Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 /PRNewswire/ -- Neurocrine...